ALSP, Inc.

ALSP, Inc. is a biotechnology company based in San Diego, California, dedicated to pioneering small molecule therapies for neurodegenerative diseases, with a particular focus on traumatic brain injury (TBI) and Alzheimer's disease (AD). The company's approach involves targeting neuroproteases in the brain to inhibit the production of harmful peptides associated with these conditions. Founded in 2002, ALSP has attracted $1.15M in debt financing investment. ALSP's innovative solutions in the treatment of neurodegenerative diseases, particularly TBI and AD, position the company as a promising player in the biotechnology, health care, and pharmaceutical sectors.